Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 7;12(22):6961.
doi: 10.3390/jcm12226961.

Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective

Dario Cocito  1 , Erdita Peci  1 , Maria Claudia Torrieri  2 , Marinella Clerico  3
Affiliations
Review

Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective

Dario Cocito et al. J Clin Med. .

Abstract

The therapeutic administration of subcutaneous immunoglobulin (SCIg) offers various advantages over intravenous immunoglobulin (IVIg). This narrative review examines and compares SCIg versus IVIg in chronic inflammatory demyelinating polyneuropathy (CIDP). SCIg is as effective as IVIg but is better tolerated and easier to administer, as intravenous access is not required. Furthermore, SCIg administration is more convenient and cost-effective than IVIg, enabling flexible treatment scheduling at home and improving patients' overall quality of life. The availability of highly concentrated immunoglobulin G (IgG) subcutaneous solutions, such as IgPro20, a 20% IgG solution stabilized with L-proline, allows for the administration of larger volumes in a single session, while the parallel development of new technological devices enables the delivery of higher doses over a shorter time. Based on the results of the PATH study, SCIg has become a well-established therapy in CIDP. In addition to discussing the advantages of SCIg, this review summarizes the evolution of SCIg by discussing all the relevant clinical studies which have considered its use in the treatment of CIDP.

Keywords: chronic inflammatory demyelinating polyneuropathy; immunoglobulin; intravenous; subcutaneous; therapy.

PubMed Disclaimer

Conflict of interest statement

D.C. received honoraria for lecturing from Baxalta, CSL Behring, and Kedrion. He received personal compensation for serving on the Advisory Board of CSL Behring, Kedrion, and Lilly, and travel grants to attend scientific meetings from Baxalta, Grifols, Kedrion, and CSL Behring. E.P. received a travel grant to attend scientific meetings from CSL Behring and Kedrion. M.C.T. has no conflict of interest. M.C. has no conflict of interest.

References

    1. Mathey E.K., Park S.B., Hughes R.A.C., Pollard J.D., Armati P.J., Barnett M.H., Taylor B.V., Dyck P.J.B., Kiernan M.C., Lin C.S.-Y. Chronic inflammatory demyelinating polyradiculoneuropathy: From pathology to phenotype. J. Neurol. Neurosurg. Psychiatry. 2015;86:973–985. doi: 10.1136/jnnp-2014-309697. - DOI - PMC - PubMed
    1. Merkies I.S.J., Hughes R.A.C., Donofrio P., Bril V., Dalakas M.C., Hanna K., Hartung H., Latov N., Van Doorn P.A., Deng C., et al. Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: The ICE study. J. Peripher. Nerv. Syst. 2010;15:208–215. doi: 10.1111/j.1529-8027.2010.00274.x. - DOI - PubMed
    1. Iijima M., Koike H., Hattori N., Tamakoshi A., Katsuno M., Tanaka F., Yamamoto M., Arimura K., Sobue G., The Refractory Peripheral Neuropathy Study Group of Japan Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J. Neurol. Neurosurg. Psychiatry. 2008;79:1040–1043. doi: 10.1136/jnnp.2007.128132. - DOI - PubMed
    1. Laughlin R.S., Dyck P.J., Melton L.J., Leibson C., Ransom J. Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology. 2009;73:39–45. doi: 10.1212/WNL.0b013e3181aaea47. - DOI - PMC - PubMed
    1. Lunn M.P.T., Manji H., Choudhary P.P., Hughes R.A.C., Thomas P.K. Chronic inflammatory demyelinating polyradiculoneuropathy: A prevalence study in south east England. J. Neurol. Neurosurg. Psychiatry. 1999;66:677–680. doi: 10.1136/jnnp.66.5.677. - DOI - PMC - PubMed

LinkOut - more resources